HCPCS Level II code J1602 denotes the unit dose for golimumab when administered intravenously (1 mg). Golimumab is a biologic agent used in clinical settings where IV delivery is required; accurate coding of J1602 is essential for billing, inventory tracking, and clinical documentation across hospital outpatient infusion centers and physician office infusion suites. Nationally, biologic infusion codes affect drug payment, prior authorization workflows, and patient cost-sharing, making precise coding important for clinicians and billing teams.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for golimumab IV administration, typical sites of service, common modifiers used with injectable drug codes, and guidance on what information is and is not available from the input. The publication outlines benchmarks and policy-relevant considerations such as payer coverage patterns, allowed billing modifiers, and coding practices that influence reimbursement and claims adjudication. Data not available in the input is explicitly noted where applicable.